Neuspera Integrated Sacral Neuromodulation System (iSNM) to Receive Same Medicare Payment as Legacy Implantable SNM Devices Under Proposed 2027 CMS Rule
Reimbursement Parity Advances Patient Access and Will Help More Patients Avoid the Pain, Complications, and Repeat Surgeries Common in the $1 Billion Legacy Sacral Neuromodulation (SNM) Market Served by Boston Scientific and Medtronic
SAN JOSE, Calif., July 8, 2026 /PRNewswire/ — Neuspera Medical today highlighted that the Centers for Medicare & Medicaid Services (CMS) has confirmed the assignment of the billing code for the Neuspera Sacral Neuromodulation System (SNM) to payment level APC 5464 in the proposed CY 2027 Outpatient Prospective Payment System Rule.1 The assignment provides the externally powered integrated SNM (iSNM) system the same Medicare payment as all other neuromodulation implantable therapies for urinary urge incontinence. The rule also increases the payment rate for APC 5464 to $22,150 for CY 2027, an 11.8% increase from 2026. Combined with the addition of the iSNM’s billing code to Medicare’s existing National Coverage Determination (NCD) 230.18 for Sacral Nerve Stimulation for Urinary Incontinence effective last year, this provides broad and straightforward access for Medicare beneficiaries for this technology.
